OnCo
peoplePerson

Evandro de Azambuja

Evandro de Azambuja is a breast oncologist who studies heart safety of HER2-targeted therapy in BIG trials.

Evandro de Azambuja works with BIG and the Institut Jules Bordet on adjuvant HER2 trials and the cardiac safety of trastuzumab-based therapy.

Role
Head of Medical Support Team, Institut Jules Bordet; Medical Oncologist
Specialisms
Breast cancerCardio-oncologyAdjuvant HER2 therapy
Profiles

Key papers

1top
rctNew England Journal of Medicine 2021changed practice
OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer

Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.

Connected

5top

Pages like this

not linked directly; found by shared links

cancers

1
HER2-positive breast cancer

technologies

1
Cardio-oncology

institutions

2
Breast International Group (BIG)Institut Jules Bordet

key papers

1
OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer